These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Visual field constriction on vigabatrin. Prescrire Int; 2000 Feb; 9(45):210-1. PubMed ID: 11503799 [TBL] [Abstract][Full Text] [Related]
4. Balancing clinical benefits of vigabatrin with its associated risk of vision loss. Pellock JM Acta Neurol Scand Suppl; 2011; (192):83-91. PubMed ID: 22061183 [TBL] [Abstract][Full Text] [Related]
5. Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry. Pellock JM; Faught E; Foroozan R; Sergott RC; Shields WD; Ziemann A; Lee D; Dribinsky Y; Torri S; Othman F; Isojarvi J Epilepsy Behav; 2016 Jul; 60():174-180. PubMed ID: 27208827 [TBL] [Abstract][Full Text] [Related]
6. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy. Sergott RC; Bittman RM; Christen EM; Sagar SM Epilepsy Res; 2010 Dec; 92(2-3):170-6. PubMed ID: 20951555 [TBL] [Abstract][Full Text] [Related]
7. Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin. Sergott RC; Westall CA Acta Neurol Scand Suppl; 2011; (192):48-56. PubMed ID: 22061180 [TBL] [Abstract][Full Text] [Related]
8. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity. Lawthom C; Smith PE; Wild JM Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223 [TBL] [Abstract][Full Text] [Related]
9. Visual impairment in children with epilepsy treated with vigabatrin. Gross-Tsur V; Banin E; Shahar E; Shalev RS; Lahat E Ann Neurol; 2000 Jul; 48(1):60-4. PubMed ID: 10894216 [TBL] [Abstract][Full Text] [Related]
11. Delayed, rapid visual field loss in a patient after ten years of vigabatrin therapy. Clayton LM; Duncan JS; Sisodiya SM; Acheson JF Eye (Lond); 2010 Jan; 24(1):185-6. PubMed ID: 19373265 [No Abstract] [Full Text] [Related]
12. Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures. Sergott RC; Johnson CA; Laxer KD; Wechsler RT; Cherny K; Whittle J; Feng G; Lee D; Isojarvi J Epilepsia; 2016 Oct; 57(10):1634-1642. PubMed ID: 27580566 [TBL] [Abstract][Full Text] [Related]
13. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)]. Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216 [TBL] [Abstract][Full Text] [Related]
14. [Changes in visual field of a child treatment with vigabatrin for 2 years]. Mrugacz M; Bakunowicz-Łazarczyk A Klin Oczna; 2003; 105(5):313-4. PubMed ID: 14746187 [TBL] [Abstract][Full Text] [Related]
15. [The function of eye and vision system in children and youth treated with vigabatrin--our own experiences]. Pojda-Wilczek D; Emich-Widera E; Herba E; Pojda SM; Marszał E Klin Oczna; 2005; 107(10-12):654-7. PubMed ID: 16619812 [TBL] [Abstract][Full Text] [Related]
16. A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience. Schwarz MD; Li M; Tsao J; Zhou R; Wu YW; Sankar R; Wu JY; Hussain SA Epilepsy Behav; 2016 Apr; 57(Pt A):29-33. PubMed ID: 26921595 [TBL] [Abstract][Full Text] [Related]
18. Vigabatrin-associated visual field defects in children. Russell-Eggitt IM; Mackey DA; Taylor DS; Timms C; Walker JW Eye (Lond); 2000 Jun; 14 ( Pt 3A)():334-9. PubMed ID: 11026995 [TBL] [Abstract][Full Text] [Related]
19. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval. Tolman JA; Faulkner MA Expert Opin Pharmacother; 2009 Dec; 10(18):3077-89. PubMed ID: 19954276 [TBL] [Abstract][Full Text] [Related]
20. The role of vigabatrin in childhood seizure disorders: results from a clinical audit. Prasad AN; Penney S; Buckley DJ Epilepsia; 2001 Jan; 42(1):54-61. PubMed ID: 11207785 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]